Atara Biotherapeutics, Inc. (ATRA): Price and Financial Metrics

Atara Biotherapeutics, Inc. (ATRA): $3.39

0.08 (+2.42%)

POWR Rating

Component Grades













Add ATRA to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where ATRA ranks best; there it ranks ahead of 83.84% of US stocks.
  • The strongest trend for ATRA is in Stability, which has been heading down over the past 179 days.
  • ATRA ranks lowest in Stability; there it ranks in the 2nd percentile.

ATRA Stock Summary

  • With a year-over-year growth in debt of 425.36%, ATARA BIOTHERAPEUTICS INC's debt growth rate surpasses 95.58% of about US stocks.
  • Revenue growth over the past 12 months for ATARA BIOTHERAPEUTICS INC comes in at 867.54%, a number that bests 98.89% of the US stocks we're tracking.
  • In terms of volatility of its share price, ATRA is more volatile than 94.87% of stocks we're observing.
  • Stocks that are quantitatively similar to ATRA, based on their financial statements, market capitalization, and price volatility, are ARCT, CRNX, RPTX, XENE, and NTLA.
  • Visit ATRA's SEC page to see the company's official filings. To visit the company's web site, go to

ATRA Valuation Summary

  • ATRA's price/sales ratio is 4.3; this is 7.53% lower than that of the median Healthcare stock.
  • ATRA's price/sales ratio has moved NA NA over the prior 97 months.

Below are key valuation metrics over time for ATRA.

Stock Date P/S P/B P/E EV/EBIT
ATRA 2022-09-23 4.3 1.2 -1.3 -1.2
ATRA 2022-09-22 4.5 1.2 -1.3 -1.3
ATRA 2022-09-21 4.7 1.3 -1.4 -1.3
ATRA 2022-09-20 5.0 1.4 -1.4 -1.4
ATRA 2022-09-19 5.0 1.4 -1.5 -1.4
ATRA 2022-09-16 5.3 1.5 -1.5 -1.5

ATRA Growth Metrics

    Its year over year price growth rate is now at -50.04%.
  • Its year over year net income to common stockholders growth rate is now at -12.35%.
  • Its 5 year net income to common stockholders growth rate is now at -263.42%.
Over the past 70 months, ATRA's revenue has gone up $71,811,000.

The table below shows ATRA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 71.811 -241.74 -247.652
2022-03-31 24.102 -239.353 -349.911
2021-12-31 20.34 -220.522 -340.141
2021-09-30 12.792 -190.373 -328.099
2021-06-30 7.422 -184.354 -317.783
2021-03-31 3.552 -179.413 -311.446

ATRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATRA has a Quality Grade of C, ranking ahead of 37.13% of graded US stocks.
  • ATRA's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • HGEN, ARMP, and ZSAN are the stocks whose asset turnover ratios are most correlated with ATRA.

The table below shows ATRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.025 1 -1.135
2021-06-30 0.015 1 -1.059
2021-03-31 0.007 1 -0.973
2020-12-31 0.000 NA -1.036
2020-09-30 0.000 NA -1.093
2020-06-30 0.000 NA -1.152

ATRA Price Target

For more insight on analysts targets of ATRA, see our ATRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.38 Average Broker Recommendation 1.41 (Moderate Buy)

ATRA Stock Price Chart Interactive Chart >

Price chart for ATRA

ATRA Price/Volume Stats

Current price $3.39 52-week high $20.04
Prev. close $3.31 52-week low $2.83
Day low $3.34 Volume 2,405,500
Day high $3.51 Avg. volume 1,616,293
50-day MA $4.05 Dividend yield N/A
200-day MA $8.63 Market Cap 319.89M

Atara Biotherapeutics, Inc. (ATRA) Company Bio

Atara Biotherapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. The company was founded in 2012 and is based in South San Francisco, California.

ATRA Latest News Stream

Event/Time News Detail
Loading, please wait...

ATRA Latest Social Stream

Loading social stream, please wait...

View Full ATRA Social Stream

Latest ATRA News From Around the Web

Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

Yahoo | September 21, 2022

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.

Yahoo | September 13, 2022

Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review

The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.

Yahoo | September 13, 2022

IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.

Yahoo | September 7, 2022

Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Yahoo | September 7, 2022

Read More 'ATRA' Stories Here

ATRA Price Returns

1-mo -15.88%
3-mo -55.28%
6-mo -63.51%
1-year -80.60%
3-year -74.80%
5-year -79.07%
YTD -78.49%
2021 -19.71%
2020 19.19%
2019 -52.59%
2018 91.93%
2017 27.46%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5923 seconds.